This site is intended for healthcare professionals
COMT inhibition in Parkinson’s Disease

Disease progression

Read time: 15 mins
Last updated:30th Nov 2020

PD progression is characterised by a worsening of motor and non-motor features, which can no longer be managed with symptomatic therapies1. Levodopa-induced motor complications are common due to increased disease severity and higher drug doses which cause a narrowing of the levodopa therapeutic window2.  

As PD advances complications related to long-term symptomatic treatment emerge, these include non-motor and motor fluctuations (Figure 1) as well as dyskinesia and psychosis1

Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest